

POSTER PRESENTATIONS

actively; $p < 0.0001$). Concerning patients treated with steroids, CLIF-OF at 3–7 days after diagnosis, was not a better predictor of 28- and 90-day mortality than Lille ROC [95% CI] 0.95 [0.86–1.00] vs 0.95 [0.85–1.00] and 0.96 [0.84–1.00], respectively).

Conclusions: AH was associated with a high short- and mid-term rate. Assessment of CLIF-OF at 3–7 days results in a more prediction of 28 and 90-day mortality than at admission. CLIF-OF may be useful predictor of mortality especially in patients treated with corticosteroids.

Mechanisms Underlying Murine and Human Acetaminophen Intoxication

Background and Aims: Acetaminophen (AP) is a commonly used non-steroidal anti-inflammatory (NSAID) drug, available both by prescription and over-the-counter. Although it is generally well-tolerated, ibuprofen can cause serious liver injury. Ibuprofen intoxication ranges from mild to severe, with serum aminotransferase levels to acute liver failure necessitating the need for liver transplantation. Thus, we aimed to investigate the molecular pathways by which ibuprofen induces ALF in mice. **Methods:** We studied clinicopathologic characteristics of patients with acetaminophen intoxication (>0.1–2 grams). Moreover, we investigated the activation of essential pathways in ibuprofen-induced liver injury (ILI) in liver sections. In parallel, we investigated ibuprofen cytotoxicity by calculating the median lethal dose (LD50) in Hepa 1–5 cells and applied it to cultures of hepatocytes isolated from C57BL/6 mice. Next, we translated the results of the *in vitro* cytotoxicity into a murine model of acetaminophen intoxication. Overnight fasted male C57BL/6 mice (6–8 weeks of age) were *ip* injected with either DMSO or 600 mg/kg

of acetaminophen. Liver samples were collected at 6, 12, and 24 hours post-injection. Liver injury was assessed by measuring serum aminotransferase levels and histological changes. In parallel, we investigated the activation of essential pathways in ibuprofen-induced liver injury (ILI) in liver sections. In parallel, we investigated ibuprofen cytotoxicity by calculating the median lethal dose (LD50) in Hepa 1–5 cells and applied it to cultures of hepatocytes isolated from C57BL/6 mice. Next, we translated the results of the *in vitro* cytotoxicity into a murine model of acetaminophen intoxication. Overnight fasted male C57BL/6 mice (6–8 weeks of age) were *ip* injected with either DMSO or 600 mg/kg

of acetaminophen. Liver samples were collected at 6, 12, and 24 hours post-injection. Liver injury was assessed by measuring serum aminotransferase levels and histological changes. In parallel, we investigated the activation of essential pathways in ibuprofen-induced liver injury (ILI) in liver sections. In parallel, we investigated ibuprofen cytotoxicity by calculating the median lethal dose (LD50) in Hepa 1–5 cells and applied it to cultures of hepatocytes isolated from C57BL/6 mice. Next, we translated the results of the *in vitro* cytotoxicity into a murine model of acetaminophen intoxication. Overnight fasted male C57BL/6 mice (6–8 weeks of age) were *ip* injected with either DMSO or 600 mg/kg

of acetaminophen. Liver samples were collected at 6, 12, and 24 hours post-injection. Liver injury was assessed by measuring serum aminotransferase levels and histological changes. In parallel, we investigated the activation of essential pathways in ibuprofen-induced liver injury (ILI) in liver sections. In parallel, we investigated ibuprofen cytotoxicity by calculating the median lethal dose (LD50) in Hepa 1–5 cells and applied it to cultures of hepatocytes isolated from C57BL/6 mice. Next, we translated the results of the *in vitro* cytotoxicity into a murine model of acetaminophen intoxication. Overnight fasted male C57BL/6 mice (6–8 weeks of age) were *ip* injected with either DMSO or 600 mg/kg

of acetaminophen. Liver samples were collected at 6, 12, and 24 hours post-injection. Liver injury was assessed by measuring serum aminotransferase levels and histological changes. In parallel, we investigated the activation of essential pathways in ibuprofen-induced liver injury (ILI) in liver sections. In parallel, we investigated ibuprofen cytotoxicity by calculating the median lethal dose (LD50) in Hepa 1–5 cells and applied it to cultures of hepatocytes isolated from C57BL/6 mice. Next, we translated the results of the *in vitro* cytotoxicity into a murine model of acetaminophen intoxication. Overnight fasted male C57BL/6 mice (6–8 weeks of age) were *ip* injected with either DMSO or 600 mg/kg

THU-304

NOVEL FUNCTION OF MITOCHONDRIAL LON PROTEASE (LONP) IN A DRUG-INDUCED DUAL MODEL OF ER-STRESS AND MITOCHONDRIAL DYSFUNCTION IN HEPATIC CELLS

M. Polo^{1,2}, F. Alegre^{1,2}, A. Marti-Rodrigo¹, A. Blas-Garcia¹⁻³, J.V. Esplugues¹⁻³, N. Apostolova^{1,3}, ¹Farmacologia, Universitat de Valencia; ²Hospital Dr. Peset, FISABIO; ³CIBERehd, Universitat de Valencia, Valencia, Spain

E-mail: nadezda.apostolova@uv.es

Background and Aims: Mitochondrial ATP-dependent protease Lon (LONP) supports cell viability during mitochondrial, oxidative and endoplasmic reticulum (ER)-stress. The non-nucleoside analog reverse transcriptase inhibitor Efavirenz (EFV), one of the most widely employed anti-HIV drugs, has been associated with hepatic toxicity linked to a mitochondrial effect accompanied by ER-stress/unfolded protein response (UPR). We investigated the abundance of mitochondria-associated ER membranes (MAMs) and LONP in an *in vitro* model of EFV exposure.

Methods: Human hepatoma cell line Hep3B was treated (24 h) with clinically relevant concentrations of EFV, comparing it with other mitochondrial stressors: Complex I inhibitor rotenone, ER-stress inductor thapsigargin and the uncoupler CCCP. Cell biology techniques (Western blot or RT-PCR) were used to analyze expression and localization of LONP and the main regulators of the mitochondrial dynamics. Co-immunoprecipitation and confocal fluorescence microscopy were employed to study MAMs.

Results: EFV enhances the presence of MAMs and alters mitochondrial dynamics. It induces mitochondrial fission and decreases fusion, detected by upregulated expression of Fis1 (Mitochondrial Fission 1 Protein), Mif (Mitochondrial Fission Factor) and Drp1 (Dynamin-Related Protein 1). A greater translocation of active Drp1 to mitochondria was observed (confocal microscopy). Markers of altered fusion were also evaluated: Optic Atrophy 1 Protein (OPA1) was induced together with its proteolysis and Mitofusin 2 (Mfn2) gene expression was augmented. MAMs were analyzed by assessing GRP75 (Heat Shock 70 kDa Protein γ), Sigma1-Receptor (Sig-1R) and the interaction of VAPB/C (Vesicle-Associated Membrane Protein-Associated Protein B/C) with PTPN51 (Protein Tyrosine Phosphatase-Interacting Protein 51) which was enhanced. Notably, both gene and protein levels of LONP were increased as was surprisingly, its presence in the cytosol. EFV response revealed both similarities and differences with other mitotoxic agents confirming the specificity of a combined ER/mitochondrial stress.

Conclusions: Specific dual mitochondria-ER effect as that triggered by the antiretroviral drug EFV enhanced MAMs content in hepatic cells, which was associated with increased extra-mitochondrial LONP expression. This is the first report of this phenomenon in mammalian cells and it may play a significant role in the hepatic adverse events related to the clinical use of EFV.

THU-305

N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AND PROGNOSIS OF ALCOHOLIC LIVER CIRRHOSIS COURSE

N. Virstyuk¹, I. Kobitovych², N. Slyvka², O. Virstyuk². ¹Therapy; ²Ivano-Frankivsk National Medical University,

Ivano-Frankivsk, Ukraine

E-mail: natalya1727@rambler.ru

Background and Aims: The brain natriuretic peptide (BNP) and its N-terminal prohormone (NT-proBNP) are sensitive markers of cardiac dysfunction. The aim of this study was to investigate the prognostic role of NT-proBNP of cardiac and renal dysfunction and liver disease severity in alcoholic liver cirrhosis (ALC) patients.

Methods: Forty-two patients with ALC in various stages II and III [median age, 59.5 yr, 21.4% females] without history of previous cardiac/ or renal disease were divided into 3 groups according to the Child-Pugh classification: grade A (n = 12), B (n = 15), and C (n = 15). ALC diagnosed by clinical, biochemical and ultrasonographic

POSTER PRESENTATIONS

findings; cardiac dysfunction - by clinical, electrocardiography and echocardiography findings; renal dysfunction - by glomerular filtration rates (GFR), serum creatinine levels and micro-/macroalbuminuria. Circulating NT-proBNP levels were measured by the immuno-assay method. ALC patients were monitored for 2 years. 12 healthy volunteers [median age, 59.2 yr, 25.0% females] were the control group.

Results: The median NT-proBNP serum levels were significantly increased in patients with decompensated ALC (grade B: 926.5 pg/mL, grade C: 1450.3 pg/mL versus grade A: 339.4 pg/mL) compared control group (66.2 pg/mL) ($p < 0.001$). The NT-proBNP levels correlated with the Child-Pugh score ($r = 0.56$, $p < 0.001$), bilirubin levels ($r = 0.48$, $p < 0.01$) and albumin levels ($r = -0.39$, $p < 0.01$). The high NT-proBNP levels in ALC patients were associated with cardiac dysfunction by reduced left ventricular (LV) ejection fraction and increased LV mass ($r = -0.41$, $p < 0.01$; $r = 0.51$, $p < 0.001$) and renal dysfunction by decreased GFR and albuminuria ($r = -0.45$, $p < 0.01$; $r = 0.36$, $p < 0.03$). In following 2 years death occurred in 2 (13.3%) of ALC patients grade B and in 7 (46.7%) of ALC patients grade C of Child-Pugh. NT-proBNP ≥ 1000 pg/mL was associated with an increased risk of death over 2 years in decompensated ALC patients (adjusted HR 2.49 [95% CI 1.25-5.88], $p = 0.03$).

Conclusions: The high NT-proBNP levels in patients with decompensated ALC may be an independent predictor of cardiac and renal dysfunction as well as severe ALC course and increased risk of death over 2 years.

THU-306 HIGH FREQUENCY OF INFLAMMATORY CD16⁺ MONOCYTES IN ALCOHOLIC HEPATITIS CAN BE REDUCED BY TREATMENT WITH PREDNISOLONE

N. Vergis¹, W. Khamri¹, C. Antoniadis¹, M. Thursz¹ and STOPAH trial group.¹ Hepatology and Gastroenterology, Imperial College, London, United Kingdom
E-mail: n.vergis@imperial.ac.uk

Background and Aims: Severe alcoholic hepatitis (SAH) is an inflammatory condition associated with the systemic inflammatory response syndrome and high serum levels of inflammatory cytokines. Accordingly, 28-day mortality in this condition can be reduced by treatment with the anti-inflammatory corticosteroid prednisolone. We sought to evaluate the impact of prednisolone versus placebo on the phenotype and function of circulating monocyte subsets in SAH.

Methods: We sampled blood from 23 patients with SAH (DF > 32) participating in the STOPAH study; 34 healthy controls (HC); and 9 patients with cirrhotic compensated alcoholic liver disease (CLD). Monoclonal antibody and FACS was used to identify monocyte subsets (classical CD14⁺CD16⁻, intermediate CD14⁺CD16⁺ and non-classical CD14^{lo}CD16⁺) and surface activation and chemokine receptor markers. Intracellular cytokine staining was used to quantify monocyte subset responses to 100 ng/mL lipopolysaccharide (LPS).

Results: The population of intermediate monocytes was expanded in SAH (11% vs 6% HC $p < 0.001$), and the frequency of patrolling non-classical monocytes was conversely diminished (1% vs 5% HC; $p < 0.0001$). Intermediate monocytes expressed higher levels of the activation marker HLA-DR (vs CLD; $p = 0.005$). Accordingly, median production of IL-1 β , IL-6 and IFN- γ in response to LPS was higher in intermediate compared to classical monocytes, and significantly for TNF- α ($p = 0.03$). These intermediate monocytes also bore higher expression of the chemokine receptor CCR-5 (vs HC; $p = 0.01$). Strikingly, the frequency of intermediate monocytes was reduced after 7 days treatment with prednisolone (15% reduced to 6%; $p = 0.05$) vs patients who were treated without prednisolone (11% to 10%; $p = 0.9$). 7 days treatment with prednisolone also reduced expression of the activation marker HLA-DR on intermediate monocytes.

without predni:
HLA-DR after 7



Conclusions: The monocyte subset novel mechanism prednisolone in high expression subset opens an inflammation with prednisolone therapy.

THU-307
NATURAL KILLER CELLS IN ALCOHOLIC LIVER DISEASE CAN BE MODULATED BY INCREASING PRO-ANGIOTENSIN II
P. Srivastava¹, R. Sehgal¹, C. Ramakrishna¹, G. G. Ramakrishna¹, G. G. Ramakrishna¹, G. G. Ramakrishna¹
¹Molecular and Cellular Medicine, Central Queensland University, Australia; ²Biology, Central Queensland University, Australia; ³Medicine, Central Queensland University, Australia; ⁴Medicine, Central Queensland University, Australia
E-mail: trehanapati@cqu.edu.au

Background and Aims: Alcoholic liver diseases (ALD) are characterized by hepatic inflammation and hepatocellular damage. Natural killer (NK) cells are a subset of lymphocytes that play a role in the regulation of endothelial progenitor cells (EPCs) and in the pathogenesis of liver disease. We aim to investigate the role of NK cells in the pathogenesis of liver disease. **Methods:** Patients with ALD were recruited under a protocol approved by the ethics committee. EPCs were cultured by flow cytometry and CD31⁺CD105⁺VEGFR2⁺ and NK cells (CD3⁻CD56⁺CD31⁻) were cultured by LDL uptake and specific modulation of EPCs was checked *in vivo* with *in vitro* culture experiments were also tested in an experimental mouse model of steatosis using mouse strain C57BL/6.
Results: Two distinct NK cell subsets were identified in the blood and liver of mice: CD45^{hi}CD31^{hi} and CD45^{lo}CD31^{lo}. The frequency of CD45^{hi}CD31^{hi} NK cells in the blood and liver of mice with ALD was significantly higher compared to saline controls ($p = 0.007$, $p = 0.002$). The frequency of CD45^{lo}CD31^{lo} NK cells in the blood and liver of mice with ALD was significantly lower compared to saline controls ($p = 0.02$, $p = 0.002$).

PROGRAMME

Alcoholic liver disease and drug-induced liver disease (cont.)

- THU-301**
YI **MCJ/DNAJC15, THE MITOCHONDRIAL FOE IN LIVER INJURY**
Lucia Barbier Torres*, Paula Iruzubieta, Daniel Taibo, Teresa Cardoso, Nicolas Navasa, David Fernández Ramos, Marta Varela Rey, Virginia Gutiérrez de Juan, Pablo Fernández Tussy, Imanol Zubiete Franco, Maria Isabel Hernández Alvarez, Raul Andrade, Inmaculada Medina, Maria Jesús Monte, José Juan García Marin, Javier Crespo, Antonio Zorzano, José María Mato, Juan Anguita, Mercedes Rincon, Maria Luz Martinez Chantar, *Spain*
- THU-302** **PREDICTING MORTALITY IN ALCOHOLIC HEPATITIS USING CLIF-ORGAN FAILURE SCORE**
Marco Silva*, Patricia Andrade, Susana Rodrigues, Armando Peixoto, Rui Gaspar, Susana Lopes, Hélder Cardoso, Guilherme Macedo, *Portugal*
- THU-303**
YI **THE MECHANISMS UNDERLYING MURINE AND HUMAN IBUPROFEN INTOXICATION**
Miguel Eugenio Zoubek*, Marius Maximilian Woitok, Raul J. Andrade, M. Isabel Lucena, Christian Trautwein, Francisco Javier Cubero, *Germany*
- THU-304** **NOVEL FUNCTION OF MITOCHONDRIAL LON PROTEASE (LONP) IN A DRUG-INDUCED DUAL MODEL OF ER-STRESS AND MITOCHONDRIAL DYSFUNCTION IN HEPATIC CELLS**
Miriam Polo, Fernando Alegre, Alberto Marti-Rodrigo, Ana Blas-Garcia, Juan V Esplugues, Nadezda Apostolova*, *Spain*
- THU-305** **N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AND PROGNOSIS OF ALCOHOLIC LIVER CIRRHOSIS COURSE**
Nataliya Virstyuk*, Iryna Kobitovych, Nataliya Slyvka, Oleg Virstyuk, *Ukraine*
- THU-306**
YI **HIGH FREQUENCY OF INFLAMMATORY CD16+ MONOCYTES IN ALCOHOLIC HEPATITIS CAN BE REDUCED BY TREATMENT WITH PREDNISOLONE**
Nikhil Vergis*, Wafa Khamri, Charalambos Antoniadis, Mark Thursz, *United Kingdom*

POSTERS / THURSDAY / APRIL 2018